Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, will present preclinical research data at the 8th Annual Los Angeles Bioscience Ecosystem Summit 2026 (“LABEST”). These findings highlight the potential of targeting deoxycytidine kinase (dCK) as a novel therapeutic approach for optic neuritis.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
